Integral Diagnostics (ITGDF) Stock Price, News & Analysis

Company Overview

Integral Diagnostics (OTCMKTS:ITGDF) is an Australia-based provider of comprehensive diagnostic imaging services, operating a network of advanced medical imaging facilities across Australia and New Zealand. The company offers a broad range of radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, nuclear medicine, positron emission tomography (PET) scanning and interventional radiology. Integral Diagnostics supports both hospital-based and standalone imaging centres, catering to a diverse patient base that includes outpatient clinics, public hospitals and private practitioners.

Founded through the consolidation of several independent radiology practices, Integral Diagnostics took its current form following an initial public offering on the Australian Securities Exchange in 2013. Since that time, the company has pursued a growth strategy centered on targeted acquisitions and organic expansion, building a network of more than 140 imaging sites. Its regional footprint spans major metropolitan markets in Queensland, New South Wales, Victoria, South Australia and Western Australia, as well as key centres in New Zealand, allowing it to serve both urban and rural communities.

Integral Diagnostics is led by a seasoned executive team headed by Chief Executive Officer Stephen Kerr, supported by functional leaders in operations, medical affairs and technology. The company’s board comprises healthcare and financial industry professionals who oversee governance, strategic planning and risk management. Integral Diagnostics maintains strong relationships with hospital networks, specialist physicians and referring clinicians to ensure coordinated patient care and continuous improvement in clinical outcomes.

Committed to investment in cutting-edge imaging technology and digital reporting platforms, Integral Diagnostics places a strong emphasis on quality assurance and patient experience. The company collaborates with research institutions to validate new diagnostic protocols and participates in ongoing professional development programs for its radiologists and technical staff. Through its integrated model, Integral Diagnostics seeks to deliver timely, accurate diagnostic information that underpins effective clinical decision-making and improves overall healthcare delivery.

Key Stats

• Today's Range: $1.00 to $1.00
• 50-Day Range: $1.00 to $2.10
• 52-Week Range: $0.96 to $2.10
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ITGDF Stock Analysis - Frequently Asked Questions

How have ITGDF shares performed this year?

Integral Diagnostics' stock was trading at $2.10 on January 1st, 2025. Since then, ITGDF stock has decreased by 52.4% and is now trading at $1.00.

How do I buy shares of Integral Diagnostics?

Shares of ITGDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ITGDF
• CIK: N/A
• Web: www.integraldiagnostics.com.au
• Phone: 61-3-5339-0704
• Fax: N/A
• Employees: 2,010
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A